CLINICAL_TRIALS
trial_result
· 2025-11-21
Clinical Trial Update: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma [Phase 1, Phase 2]
Summary
A Phase 1/2 study evaluating APX005M in combination with pembrolizumab for metastatic melanoma has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-11-21